期刊文献+

大蒜素对骨肉瘤获得性耐药细胞株的作用及其机制 被引量:2

Effects of diallyl trisulfide on osteosarcoma acquired drug-resistant cell line and its possible mechanism
下载PDF
导出
摘要 目的探讨大蒜素(DATS)对骨肉瘤获得性耐药细胞株的作用及其机制。方法体外间歇刺激法建立对阿霉素(DOX)产生获得性耐药的骨肉瘤细胞株Saos-2/DOX,MTT法检测DOX对Saos-2及Saos-2/DOX细胞的半数抑制浓度(IC50),并计算Saos-2/DOX细胞的耐药指数(RI);MTT法筛选DATS处理Saos-2/DOX细胞的非细胞毒性浓度;DATS与DOX单独或联合干预Saos-2/DOX细胞24、48、72 h后,MTT法检测细胞生存率;不同浓度DATS(0、10、50、100μmol/L)处理Saos-2/DOX细胞48 h后,Western blotting法检测细胞中p ERK1/2、ERK1/2、p AKT1和AKT1蛋白表达。结果成功建立对DOX耐药的骨肉瘤细胞株Saos-2/DOX,细胞的RI值为6.94。DATS干预Saos-2/DOX细胞的非细胞毒性浓度为10μmol/L。DOX 100μg/L与DATS 10μmol/L联合处理Saos-2/DOX耐药细胞24 h后细胞存活率显著低于DATS 10μmol/L或DOX 100μg/L单独处理,且随处理时间延长逐渐降低(P均<0.05)。不同浓度DATS处理Saos-2/DOX细胞48 h后,ERK1/2、p AKT1和AKT1蛋白表达变化差异无统计学意义(P均>0.05),而p ERK1/2蛋白表达水平随DATS浓度增高显著增加(P均<0.05)。结论 DATS可能通过激活ERK1/2信号通路,逆转Saos-2/DOX细胞的获得性耐药。 Objective To observe the effects of diallyl trisulfide( DATS) on the osteosarcoma acquired drug-resistance cell line,and to investigate its possible mechanism. Methods We established an osteosarcoma cell line Saos-2/DOX which acquired drug-resistance to doxorubicin( DOX) in vitro by the pulse selection. MTT assay was applied to determine the half maximal inhibitory concentration( IC50) of Doxorubicin( DOX) on the Saos-2 and Saos-2/DOX cells,besides the resistance index( RI) of Saos-2/DOX was calculated. Moreover,the DATS concentration treating Saos-2/DOX without cytotoxicity was selected by MTT assay. The cell viability was detected by MTT assay at 24,48,and 72 h after the treatment of DOX alone or in combination with DATS on the Saos-2/DOX cells. At 48 h after the treatment of DATS( 0,10,50,and 100 μmol/L) on the Saos-2/DOX cells,the protein expression levels of p ERK1/2,ERK1/2,p AKT1,and AKT1 were detected by Western blotting. Results The DOX-resistant osteosarcoma cell line Saos-2/DOX was successfully established and the RI of Saos-2/DOX was 6. 94. The DATS concentration treating Saos-2/DOX cells without cytotoxicity was 10 μmol/L. The survival rate of Saos-2/DOX-resistant cells treated with DOX 100 μg/L and DATS 10 μmol/L for 24 h was significantly lower than that of DOXS 10 μmol/L or DOX 100 μg/L,and decreased over the treatment time( all P〈0. 05). At 48 h after treatment of different concentrations of DATS,the protein expression level of p ERK1/2 was significantly up-regulated,which was concentration dependent( P〈0. 05). However,no significant difference was found in the protein expression levels of ERK1/2,p AKT1,and AKT1( all P〉0. 05). Conclusion DATS could reverse the acquired drug-resistance of Saos-2/DOX cells by activating the ERK1/2 signal pathway.
作者 李季 蔡锦芳 邹林 李宗玉 LI Ji;CAI Jinfang;ZOU Lin;LI Zongyu(The First People's Hospital of Zhengzhou, Zhengzhoa 450004, China)
出处 《山东医药》 CAS 2018年第1期23-26,共4页 Shandong Medical Journal
基金 国家自然科学基金资助项目(30973018)
关键词 骨肿瘤 大蒜素 获得性耐药细胞 细胞外调节蛋白激酶1/2信号通路 bone neoplasms diallyl trisulfide acquired drug-resistant cells extracelluar regulated protein kinases1/2 sigualing pathway
  • 相关文献

参考文献2

二级参考文献12

  • 1Ferguson WS, Goorin AM. Current treatment of osteosarcoma [ J ]. Cancer Invest, 2001,19 ( 3 ) :292 - 315.
  • 2Bramwell VH. Osteosarcomas and other cancers of bone [ J ]. Curr Opin Oncol, 2000,12 (4) : 330 - 336.
  • 3Bacci G, Ferrari S, Bertoni F, et al. Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the Istituto Ortopedico Rizzoli according to the Istituto Ortopedico Rizzoli/osteosarcoma-2 protocol: an updated report [ J]. Clin Oncol, 2000, 18 (24) :4016 -4027.
  • 4Bacci G, Briccoli A, Fen'ari S, et al. Neoadjuvant chemotherapy for osteosareoma of the extremities with synchronous lung metastases: treatment with cisplatin, adriamycin and high dose of methotrexate and ifosfamide[J]. Oncol Rep ,2000,7 (2) :339 - 346.
  • 5Bielack SS, Kempf-Bielack B, Delling G, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk : An analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols[J]. J Clin Oncol, 2002,20(3) : 776 -790.
  • 6Gorlick R, Goker E, Trippett T, et al. defecitve transport is a common mechanism of acquired methotrexate resistance in acute lymphocytic leukemia and is associated with decreased reduced folate carrier expression [ J ]. Blood, 1997,89 (3) : 1013 - 1018.
  • 7Bertino JR, Karnofsky memorial lecture. Ode to methotrexate [ J 1. Clin Oncol, 1993,11 ( 1 ) :5 - 14.
  • 8Banerjee D, Mayer-Kuckuk P, Capiaux G, et al. Retroviral transduction of a mutant dihydrofolate reductase-thymidylate synthase fusion gene into routine marrow ceils confers resistance to both methotrexate and 5-fluorouracil[ J]. Hum Gene Ther, 2003,14(5 ) :435 - 446.
  • 9Wijnholds J, Mol CA, van Deemter L, et al Muhidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nncleotide analogs[J].Proc Natl Acad Sci USA, 2000,97 ( 13 ) : 7476 - 7481.
  • 10Snow K, Judd W. Characterization of adriamycin- and amsacrine- resistant human leukaemic T cell lines [ J ]. Br J Cancer, 1991,63 (1): 17-28.

共引文献26

同被引文献24

引证文献2

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部